Study of Pembrolizumab and M032 (NSC 733972)

This study is testing a combination of pembrolizumab (an immunotherapy drug) with M032 — a specially engineered virus that is designed to infect and kill brain tumor cells — in people with aggressive brain cancers like glioblastoma. **You may be eligible if...** - You have been diagnosed with glioblastoma, anaplastic astrocytoma, or gliosarcoma - For people with recurrent cancer: your tumor has come back and you are a candidate for surgery to remove it again, and you have already received radiation and chemotherapy - For newly diagnosed patients: scans suggest you have a malignant brain tumor and surgery is planned as part of your treatment - You have completed any prior radiation or chemotherapy at least 4 weeks before starting the study **You may NOT be eligible if...** - Your prior treatment with nitrosourea-type chemotherapy was completed fewer than 6 weeks ago - Your tumor is not confirmed to be one of the qualifying diagnoses - You are unable to tolerate surgery - You have other serious health conditions that would make participation unsafe Talk to your doctor to see if this trial is right for you.